Latest Strategic Reviews News

Percheron Therapeutics posted a 25% increase in net loss for FY2025 amid termination of its Duchenne Muscular Dystrophy programs. The company pivots strategically to oncology with the in-licensing of HMBD-002, a monoclonal antibody targeting VISTA, aiming to initiate Phase II trials in 2026.

Resimac Group reported a 13% rise in operating profit for FY25, driven by strong asset growth and a major auto finance acquisition, while declaring a total dividend of 19 cents per share.

Raiz Invest Limited reported robust FY25 results with revenue up 14.5% and underlying EBITDA surging 147.5%, while completing its exit from Southeast Asia and launching the new Raiz Lite product.

Ramsay Health Care posted solid revenue growth driven by its Australian and UK hospital businesses, despite a significant impairment charge impacting net profit. The group advances a multi-year transformation focusing on operational efficiency and capital discipline.

Ramsay Health Care reported a 6.8% revenue increase and a modest rise in underlying profit for FY25, despite a significant impairment in its UK mental health division. The company maintains a strong dividend and outlines a cautiously optimistic outlook for FY26.

Urbanise.com Limited reported a 4.2% revenue increase and a 77% improvement in adjusted EBITDA loss for FY2025, driven by new contracts and a key partnership with NAB. The company ended the year cash flow positive with a strong balance sheet, setting the stage for a transformative product launch in 2026.

Xref Limited reported a significantly reduced net loss for FY2025 and a return to positive EBITDA, driven by strategic cost restructuring and a transition to a SaaS business model.

Aquirian Limited reported a 13% revenue increase to $26.1 million in FY25, securing a $20 million three-year contract with a Western Australian goldmine and advancing its innovative Collar Keeper® technology.

Aquirian Limited reported a 12.6% revenue increase to $26.07 million for FY25 but posted a $3.41 million statutory loss amid ramp-up costs and impairments. The company is advancing its Energetics and Technology divisions, including the Wubin Emulsion Facility and Collar Keeper® System.

NextEd Group reported a 13.9% revenue decline in FY25, yet maintained resilient EBITDA and strengthened its cash position, signaling a strategic reset underway to capture future growth.

M3 Mining Limited has announced a significant leadership renewal alongside a strategic review aimed at streamlining operations, reducing costs, and focusing on high-value exploration assets.

Mach7 Technologies reported a robust FY25 with 16% revenue growth and a strategic pivot towards customer-centric innovation, underpinned by leadership changes and a strong financial position.